Intra-Cellular Therapies Inc. (ITCI)
Stock Price:
$19.78 USD
0.43 (2.22%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $19.40 -0.38 (-1.92%) Aug 13, 7:43 PM
Key Info
| Market Cap |
1.33B |
| Revenue (ttm) |
3.05M |
| Net Income (ttm) |
-186.57M |
| Shares Out |
67.31M |
| EPS (ttm) |
-3.08 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$19.78 |
| Previous Close |
$19.35 |
| Change ($) |
0.43 |
| Change (%) |
2.22% |
| Day's Open |
19.35 |
| Day's Range |
19.27 - 19.89 |
| Day's Volume |
454,054 |
| 52-Week Range |
6.75 - 43.56 |
More Stats
| Market Cap |
1.33B |
| Enterprise Value |
947.29M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
67.31M |
| Float |
59.13M |
| EPS (basic) |
-3.06 |
| EPS (diluted) |
-3.08 |
| FCF / Share |
-2.45 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.31M |
| Short Ratio |
7.03 |
| Short % of Float |
8.35% |
| Beta |
1.79 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
436.39 |
| PB Ratio |
3.36 |
| Revenue |
3.05M |
| Operating Income |
-192.10M |
| Net Income |
-186.57M |
| Free Cash Flow |
-162.89M |
| Net Cash |
384.03M |
| Net Cash / Share |
5.71 |
| Gross Margin |
-2,919.44% |
| Operating Margin |
-6,296.95% |
| Profit Margin |
-6,115.50% |
| FCF Margin |
-5,339.35% |
| ROA |
-31.98% |
| ROE |
-58.64% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
9 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$45.25*
(128.77% upside)
Low
32.0
Current: $19.78
High
70.0
Target: 45.25
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | 0.06 | - | 0.25 | 0.33 | 0.09 | 0.58 | 2.74 | 3.12 | 23.36 |
| Revenue Growth | - | - | -25.66% | 261.96% | -84.17% | -78.91% | -12.22% | -86.65% | - |
| Gross Profit | 0.06 | - | 0.25 | 0.33 | 0.09 | 0.58 | 2.74 | 3.12 | 23.36 |
| Operating Income | -154 | -162 | -103 | -118 | -106 | -30.99 | -26.27 | -16.40 | 11.09 |
| Net Income | -148 | -155 | -97.77 | -116 | -105 | -30.69 | -26.87 | -16.59 | 11.09 |
| Shares Outstanding | 55.19 | 54.71 | 46.18 | 43.24 | 36.07 | 28.65 | 17.26 | 5.61 | 11.20 |
| Earnings Per Share | -2.68 | -2.84 | -2.12 | -2.69 | -2.91 | -1.07 | -1.56 | -2.96 | 0.33 |
| Operating Cash Flow | -128 | -118 | -80.49 | -91.26 | -102 | -22.81 | -22.59 | -18.90 | 16.20 |
| Capital Expenditures | -0.70 | -0.39 | -0.72 | -0.05 | -0.86 | -0.01 | -0.03 | -0.04 | -0.02 |
| Free Cash Flow | -129 | -119 | -81.22 | -91.31 | -103 | -22.82 | -22.62 | -18.94 | 16.19 |
| Cash & Equivalents | 224 | 348 | 464 | 384 | 475 | 130 | 37.15 | 19.15 | 22.89 |
| Total Debt | 23.14 | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 201 | 348 | 464 | 384 | 475 | 130 | 37.15 | 19.15 | 22.89 |
| Assets | 251 | 357 | 471 | 389 | 484 | 131 | 38.45 | 19.82 | 23.59 |
| Liabilities | 56.18 | 39.49 | 17.05 | 13.40 | 7.86 | 10.56 | 6.83 | 2.84 | 34.84 |
| Book Value | 195 | 318 | 454 | 376 | 476 | 121 | 31.62 | 16.98 | -11.25 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Intra-Cellular Therapies Inc. |
| Country |
United States |
| Employees |
330 |
| CEO |
Sharon Mates |
Stock Information
| Ticker Symbol |
ITCI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ITCI |
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company is developing its lead drug candidate, CAPLYTA for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.